Maternal and Newborn Safety Profile of Progestogens in EARLY Pregnancy

NCT ID: NCT05186779

Last Updated: 2023-08-14

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-12-15
• Study Completion Date: 2023-07-14

Brief Summary

This multinational, prospective, active surveillance, registry study following two cohorts will include study participants who are pregnant and seeking any type of medical treatment, including dydrogesterone and other progestogens, for either (A) recurrent pregnancy loss and/or bleeding in early pregnancy or (B) as In-Vitro Fertilization (IVF)/Assissted Reproductive Technology (ART) support. Pregnant women not taking progestogen and are advised an alternative non-medical treatment, in the context of bleeding in early pregnancy, recurrent pregnancy loss, or undergoing natural cycle frozen embryo transfer (NC-FET) can also be included in this study. Eligible study participants will be recruited via an international network of prescribing Health Care Practitioners (HCPs) in China, Turkey, and Russia with the aim to collect data related to maternal safety and newborn safety in women prescribed progestogens during early pregnancy. Study participants will be followed from early pregnancy until 6 - 12 weeks after giving birth. All malformations will be captured via direct contacts with the study participants. Study participants will be sent online questionnaires via the electronic Patient Reported Outcomes (ePRO) solution provided by MediData. Major malformations reported by the study participants will be validated by ZEG Berlin via relevant source documents and if necessary, via contacting the treating HCPs. The total study duration is planned for approximately 4 years including recruitment and follow-up.

Conditions

Early Pregnancy Bleeding; Recurrent Pregnancy Loss

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Cohort A

Early Pregnancy Bleeding/Recurrent Pregnancy loss

Progestagen

Intervention Type: DRUG

Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer

Cohort B

IVF/ART

Progestagen

Intervention Type: DRUG

Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer

Interventions

Progestagen

Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer

Intervention Type: DRUG

Other Intervention Names

Any other treatment for the indication as per cohort A or cohort B

Eligibility Criteria

Inclusion Criteria

• Pregnant women who wish to sustain their pregnancy
• Women who have tested positive (blood or urine) for pregnancy in the first trimester
• treated with progestogens or any alternative treatment for early bleeding in pregnancy with evidence of an intrauterine pregnancy / unexplained recurrent OR pregnancy loss (with ≥ 2 previous pregnancy losses) with evidence of an intrauterine pregnancy OR having undergone IVF/ ART embryo transfer and taking progestogen for luteal phase support (LPS), with evidence of an intrauterine pregnancy
• Signed informed consent, allowing consent to contact all treating, or diagnosing HCP
• Able and willing to read and comprehend written instructions; comprehend and complete the questionnaires required by the protocol

Exclusion Criteria

• Serious disease or disease requiring teratogenic treatment (e.g., Lupus Erythematosus, Multiple Sclerosis, cancer)
• Multifetal pregnancy
• More than four (4) previous IVF embryo transfers
• Previous exposure to dydrogesterone in index pregnancy
• Documented substance abuse
• Treatment with hormones which are known to cause malformations
• Participation in an observational study that might, in the recruiting HCP's opinion, influence the assessment for the current study
• Participation in a randomized clinical trial in the last 3 months
• Previous enrollment in the PEARLY study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Abbott Products Operations AG

UNKNOWN

Sponsor Role: collaborator

Center for Epidemiology and Health Research, Germany

OTHER

Sponsor Role: lead

Responsible Party

Clare Barnett, MBBS (Hons) MPH

Dr. Clare Barnett

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Clare Barnet

Role: PRINCIPAL_INVESTIGATOR

ZEG

Locations

Center for Epidemiology and Health Research Berlin

Berlin, , Germany

Countries

Germany

Other Identifiers

DYDR5007

Identifier Type: -

Identifier Source: org_study_id